Organizing Committee Members - ONCOLOGISTS CONGRESS 2020
Ukrainian Anti-Cancer Institute
Dr. Wassil Nowicky(Biography)
Wassil Nowicky is the Director of Nowicky Pharma and President of the Ukrainian Anti-Cancer Institute (Vienna, Austria). He has finished his study at the Radiotechnical Faculty of the Technical University of Lviv (Ukraine) by the end of 1955 from graduation to Diplomingeniueur in 1960 whose title was nostrificated in Austria in 1975. He is the Author of over 300 scientific articles dedicated to cancer research. He is a real member of the New York Academy of Sciences, member of the European Union for Applied Immunology and of the American Association for scientific progress, Honorary Doctor of the Janka Kupala University in Hrodno, doctor honoris causa of the Open international university on Complex Medicine in Colombo, Honorary Member of the Austrian Society of a name od Albert Schweizer. He has received the award for merits of National guild of pharmacists of America. the award of Austrian Society of sanitary, hygiene and publichealth services and others.
Dr. Wassil Nowicky(Research Area)
Oncology, Cancer, Immuno Oncology.
M G Hanna(Biography)
Dr. Michael G. Hanna, Jr., Ph.D., founded Vaccinogen, Inc. in 2007 and served as its Chairman and Chief Executive Officer until August 2014. Dr. Hanna served as the Chief Scientific Officer of Vaccinogen, Inc., and served as its Chief Executive Officer until October 1st 2010. He served as the Chief Scientific Officer of Intracel Holdings Corporation. He served as the Chairman of the Board, Chief Executive Officer and President of PerImmune, Inc. He served as President of Intracel Holdings Corporation. From 1985 to 1994, he was the Chief Operating Officer of Organon Teknika/Biotechnology Research Institute. He founded the Litton Institute of Applied Biotechnology (LIAB), which Organon Teknika acquired in 1985 and was a Senior Vice President at Organon Teknika. Dr. Hanna served as the Chairman of Intracel Holdings Corporation. Dr. Hanna served as Chairman Emeritus at Vaccinogen, Inc. since August 2014 at Vaccinogen, Inc. and also served as its Director and Member of Medical Advisory Board until September 29, 2017. He served as a Director of the National Cancer Institute From 1975 to 1983, Frederick Cancer Research Center.
M G Hanna(Research Area)
University of the Rockies
Consultant- Pediatric Oncology-Hematology
King Fahd Specialist Hospital Dammam
Reema Al Hayek(Biography)
Dr. Reema Al Hayek is a Consultant Pediatric Oncology-Hematology and Stem Cell Transplant. She obtained her bachelor degree in Medicine, (June 1983), she was board certified in Pediatrics (Dec. 1987), Assistant Professor in General Pediatrics (Feb. 1988), Board Certified (DISC) in Pediatric Oncology Sub-Specialty at University of Rene Descartes Paris (June 1991). She obtained as well many other certifications as for the Diploma of Oncologic Pharmacology from the University of Lariboisier, St. Louis, Paris (June 1991), the Diploma in Experimental Hematology (Transfection of Genes and Trans-genesis, and Genotherapy) from the University of Rene Descartes, Paris (June 1991). She obtained the degree of Assistant Professor in Pediatric Oncology University of Paris South (June 1991) and her Executive Master in Health Administration Science in December 2013 During her working years she was assigned to the following administrative positions; Director of Medical Services at KFSHD (2015-now), Director Oncology Center, KFSHD (2010-2015), Founder and Chairwoman of the Pediatric Oncology - Hematology Department, KFSHD ( 2006-2010), Founder and Chairwoman of the department of Pediatric, KFSHD( 2005-2006). She was the Director of the Pediatric Residency Training Program from 1995 for 10 consecutive years and currently is an active member of the fellowship program for the Pediatric Hematology Oncology During her past 25 years of Clinical Experience she has developed a high expertise in Pediatric Oncology Solid Tumors, Benign Hematology and Leukemia, her field of interest in Researches is in the Hodgkin Disease and its specificity in Saudi Arabia mainly in the Eastern Province through an ongoing Epidemiological Study, other fields of interest is in the leukemia and its treatment response and genetic characteristic in Saudi Arabia multicenter study has been published. Monoclonal Target Therapy mainly in refractory or in relapsing Leukemia and in Chemotherapy Resistant Hodgkin Lymphoma and Multidrug Resistance in Acute Lymphoblastic Leukemia. Dr. Al Hayek is an active member in the following societies: member of the Pediatric Saudi Association SAPHOS (2000 till now), member of the Regional Pediatric OncologyÃ¢â‚¬â€œHematology MECCA Group (2000 till now), member of Sanad Scientific Committee for the National Pediatric Oncology Hematology Research Grant Allocation, member of the Organizing Committee for Sanad Annual National Symposium for Pediatric Hematology Oncology, member of the International Society of Pediatric Oncology SIOP (since 1997), member of the Franco Ã¢â‚¬â€œ Arab Society of Cancer (since 1991), member of Pediatric Oncology Society of the Developing Country Group PODC (since 1997), member of Pediatric Society of Oncology, Asian Group (since 1997), member of French Society of Pediatric Oncology, SFOP (since 1991), member of Children Oncology Group COG of United States (since 2008 till 2016), Founding Member in Poem Association of the Mediterranean, Regional and Gulf Group (Nov.2013)
Reema Al Hayek(Research Area)
Hodgkin Disease and its specificity, leukemia and its treatment response and genetic characteristic
David I Smith(Biography)
David I Smith received his B.S. In Mathematics and Molecular Biology from the University of Wisconsin in Madison. He then went on to get his Ph.D. In Biochemistry, also at the UW Madison in 1978. His first faculty position was at Wayne State University in Detroit. For the past 22 years he has been a Professor in the Department of Laboratory Medicine and Pathology at the Mayo Clinic. He is also the Chairman of the Technology Assessment Group for the Mayo Clinic Center for Individualized Medicine. His laboratory studies genome inability and the common fragile sites and their role in cancer development. His laboratory also studies the different ways the human papillomavirus is involved in the development of different cancers. The tools that Dr. SmithÃ¢â‚¬â„¢s laboratory uses to address these questions is massively parallel next generation sequencing.
David I Smith(Research Area)
Current Projects :- Oropharyngeal cancer, Long noncoding RNA.